Diabetes Testing Program - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511248994

Publication Date:

November 22, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

A program for detecting diabetes, generally including fasting plasma glucose test, oral glucose tolerance test, etc.
The global market for Diabetes Testing Program was estimated to be worth US$ 2106.6 million in 2023 and is forecast to a readjusted size of US$ 2956.2 million by 2030 with a CAGR of 5.4% during the forecast period 2024-2030
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents鈥� wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Diabetes Testing Program, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Diabetes Testing Program by region & country, by Type, and by Application.
The Diabetes Testing Program market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diabetes Testing Program.
麻豆原创 Segmentation
By Company
InSphero AG
Abbott Laboratories
American Laboratory Products Company (ALPCO)
Beckmann Coulter Inc.
Bio-Rad Laboratories Inc.
Ortho Clinical Diagnostics Inc.
F. Hoffmann-la Roche Ltd
Siemens AG
PTS Diagnostics
Segment by Type:
Instruments
Testing Kits
Reagent
Segment by Application
Hospitals
Specialty Clinics
Diagnostic Centers
麻豆原创 Care Settings
Academic Research Institutes
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Diabetes Testing Program manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Diabetes Testing Program in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Diabetes Testing Program in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Diabetes Testing Program Product Introduction
1.2 Global Diabetes Testing Program 麻豆原创 Size Forecast
1.3 Diabetes Testing Program 麻豆原创 Trends & Drivers
1.3.1 Diabetes Testing Program Industry Trends
1.3.2 Diabetes Testing Program 麻豆原创 Drivers & Opportunity
1.3.3 Diabetes Testing Program 麻豆原创 Challenges
1.3.4 Diabetes Testing Program 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Diabetes Testing Program Players Revenue Ranking (2023)
2.2 Global Diabetes Testing Program Revenue by Company (2019-2024)
2.3 Key Companies Diabetes Testing Program Manufacturing Base Distribution and Headquarters
2.4 Key Companies Diabetes Testing Program Product Offered
2.5 Key Companies Time to Begin Mass Production of Diabetes Testing Program
2.6 Diabetes Testing Program 麻豆原创 Competitive Analysis
2.6.1 Diabetes Testing Program 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Diabetes Testing Program Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diabetes Testing Program as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Instruments
3.1.2 Testing Kits
3.1.3 Reagent
3.2 Global Diabetes Testing Program Sales Value by Type
3.2.1 Global Diabetes Testing Program Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Diabetes Testing Program Sales Value, by Type (2019-2030)
3.2.3 Global Diabetes Testing Program Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Specialty Clinics
4.1.3 Diagnostic Centers
4.1.4 麻豆原创 Care Settings
4.1.5 Academic Research Institutes
4.2 Global Diabetes Testing Program Sales Value by Application
4.2.1 Global Diabetes Testing Program Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Diabetes Testing Program Sales Value, by Application (2019-2030)
4.2.3 Global Diabetes Testing Program Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Diabetes Testing Program Sales Value by Region
5.1.1 Global Diabetes Testing Program Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Diabetes Testing Program Sales Value by Region (2019-2024)
5.1.3 Global Diabetes Testing Program Sales Value by Region (2025-2030)
5.1.4 Global Diabetes Testing Program Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Diabetes Testing Program Sales Value, 2019-2030
5.2.2 North America Diabetes Testing Program Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Diabetes Testing Program Sales Value, 2019-2030
5.3.2 Europe Diabetes Testing Program Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Diabetes Testing Program Sales Value, 2019-2030
5.4.2 Asia Pacific Diabetes Testing Program Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Diabetes Testing Program Sales Value, 2019-2030
5.5.2 South America Diabetes Testing Program Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Diabetes Testing Program Sales Value, 2019-2030
5.6.2 Middle East & Africa Diabetes Testing Program Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Diabetes Testing Program Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Diabetes Testing Program Sales Value
6.3 United States
6.3.1 United States Diabetes Testing Program Sales Value, 2019-2030
6.3.2 United States Diabetes Testing Program Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Diabetes Testing Program Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Diabetes Testing Program Sales Value, 2019-2030
6.4.2 Europe Diabetes Testing Program Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Diabetes Testing Program Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Diabetes Testing Program Sales Value, 2019-2030
6.5.2 China Diabetes Testing Program Sales Value by Type (%), 2023 VS 2030
6.5.3 China Diabetes Testing Program Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Diabetes Testing Program Sales Value, 2019-2030
6.6.2 Japan Diabetes Testing Program Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Diabetes Testing Program Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Diabetes Testing Program Sales Value, 2019-2030
6.7.2 South Korea Diabetes Testing Program Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Diabetes Testing Program Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Diabetes Testing Program Sales Value, 2019-2030
6.8.2 Southeast Asia Diabetes Testing Program Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Diabetes Testing Program Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Diabetes Testing Program Sales Value, 2019-2030
6.9.2 India Diabetes Testing Program Sales Value by Type (%), 2023 VS 2030
6.9.3 India Diabetes Testing Program Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 InSphero AG
7.1.1 InSphero AG Profile
7.1.2 InSphero AG Main Business
7.1.3 InSphero AG Diabetes Testing Program Products, Services and Solutions
7.1.4 InSphero AG Diabetes Testing Program Revenue (US$ Million) & (2019-2024)
7.1.5 InSphero AG Recent Developments
7.2 Abbott Laboratories
7.2.1 Abbott Laboratories Profile
7.2.2 Abbott Laboratories Main Business
7.2.3 Abbott Laboratories Diabetes Testing Program Products, Services and Solutions
7.2.4 Abbott Laboratories Diabetes Testing Program Revenue (US$ Million) & (2019-2024)
7.2.5 Abbott Laboratories Recent Developments
7.3 American Laboratory Products Company (ALPCO)
7.3.1 American Laboratory Products Company (ALPCO) Profile
7.3.2 American Laboratory Products Company (ALPCO) Main Business
7.3.3 American Laboratory Products Company (ALPCO) Diabetes Testing Program Products, Services and Solutions
7.3.4 American Laboratory Products Company (ALPCO) Diabetes Testing Program Revenue (US$ Million) & (2019-2024)
7.3.5 Beckmann Coulter Inc. Recent Developments
7.4 Beckmann Coulter Inc.
7.4.1 Beckmann Coulter Inc. Profile
7.4.2 Beckmann Coulter Inc. Main Business
7.4.3 Beckmann Coulter Inc. Diabetes Testing Program Products, Services and Solutions
7.4.4 Beckmann Coulter Inc. Diabetes Testing Program Revenue (US$ Million) & (2019-2024)
7.4.5 Beckmann Coulter Inc. Recent Developments
7.5 Bio-Rad Laboratories Inc.
7.5.1 Bio-Rad Laboratories Inc. Profile
7.5.2 Bio-Rad Laboratories Inc. Main Business
7.5.3 Bio-Rad Laboratories Inc. Diabetes Testing Program Products, Services and Solutions
7.5.4 Bio-Rad Laboratories Inc. Diabetes Testing Program Revenue (US$ Million) & (2019-2024)
7.5.5 Bio-Rad Laboratories Inc. Recent Developments
7.6 Ortho Clinical Diagnostics Inc.
7.6.1 Ortho Clinical Diagnostics Inc. Profile
7.6.2 Ortho Clinical Diagnostics Inc. Main Business
7.6.3 Ortho Clinical Diagnostics Inc. Diabetes Testing Program Products, Services and Solutions
7.6.4 Ortho Clinical Diagnostics Inc. Diabetes Testing Program Revenue (US$ Million) & (2019-2024)
7.6.5 Ortho Clinical Diagnostics Inc. Recent Developments
7.7 F. Hoffmann-la Roche Ltd
7.7.1 F. Hoffmann-la Roche Ltd Profile
7.7.2 F. Hoffmann-la Roche Ltd Main Business
7.7.3 F. Hoffmann-la Roche Ltd Diabetes Testing Program Products, Services and Solutions
7.7.4 F. Hoffmann-la Roche Ltd Diabetes Testing Program Revenue (US$ Million) & (2019-2024)
7.7.5 F. Hoffmann-la Roche Ltd Recent Developments
7.8 Siemens AG
7.8.1 Siemens AG Profile
7.8.2 Siemens AG Main Business
7.8.3 Siemens AG Diabetes Testing Program Products, Services and Solutions
7.8.4 Siemens AG Diabetes Testing Program Revenue (US$ Million) & (2019-2024)
7.8.5 Siemens AG Recent Developments
7.9 PTS Diagnostics
7.9.1 PTS Diagnostics Profile
7.9.2 PTS Diagnostics Main Business
7.9.3 PTS Diagnostics Diabetes Testing Program Products, Services and Solutions
7.9.4 PTS Diagnostics Diabetes Testing Program Revenue (US$ Million) & (2019-2024)
7.9.5 PTS Diagnostics Recent Developments
8 Industry Chain Analysis
8.1 Diabetes Testing Program Industrial Chain
8.2 Diabetes Testing Program Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Diabetes Testing Program Sales Model
8.5.2 Sales Channel
8.5.3 Diabetes Testing Program Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

InSphero AG
Abbott Laboratories
American Laboratory Products Company (ALPCO)
Beckmann Coulter Inc.
Bio-Rad Laboratories Inc.
Ortho Clinical Diagnostics Inc.
F. Hoffmann-la Roche Ltd
Siemens AG
PTS Diagnostics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.